“It was vitamin E and selenium in 2011-2012. There was a lot of hype about it. People were very excited. They lost their excitement in urology about it, but then along came vitamin D,” says Mark A. Moyad, MD, MPH.
In this interview, Mark A. Moyad, MD, MPH discusses the 2011 Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the recently completed VITamin D and OmegA-3 TriaL (VITAL), both of which explored the impact of vitamin D on urologic endpoints. Moyad is the Jenkins/Pomkempner Director of Complementary Alternative Medicine in the Department of Urology at the University of Michigan Medical Center.
Urologists and radiation oncologists often differ in prostate cancer treatment recommendations
January 31st 2023“If there is such a clear difference between what different physicians are recommending, that calls into the need for patients to be more involved in decisions,” says Angela Fagerlin, PhD.
2 Clarke Drive
Cranbury, NJ 08512